Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

📖 Wiki Page

therapeutic2921 wordssynced 2026-04-02

Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP</th>
</tr>
<tr>
<td class="label">ATP Concentration</td>
<td>Primary Receptors Activated</td>
</tr>
<tr>
<td class="label">1-10 nM</td>
<td>Adenosine (P1) receptors</td>
</tr>
<tr>
<td class="label">100 nM - 1 μM</td>
<td>P2Y receptors</td>
</tr>
<tr>
<td class="label">10-100 μM</td>
<td>P2X1-6 receptors</td>
</tr>
<tr>
<td class="label">1-10 mM</td>
<td>P2X7 receptor</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Agonist</td>
</tr>
<tr>
<td class="label">P2Y1</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">P2Y2</td>
<td>ATP, UTP</td>
</tr>
<tr>
<td class="label">P2Y4</td>
<td>UTP</td>
</tr>
<tr>
<td class="label">P2Y6</td>
<td>UDP</td>
</tr>
<tr>
<td class="label">P2Y11</td>
<td>ATP</td>
</tr>
<tr>
<td class="label">P2Y12</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">P2Y13</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">P2Y14</td>
<td>UDP-glucose</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">JNJ-47965567</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">AZD106</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">CE-224535</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="lab

...

Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

Overview

Purinergic signaling represents a critical modulatory system in the central nervous system that plays a pivotal role in neuronal communication, glial function, and neuroinflammation. In the context of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4R-tauopathies, purinergic signaling pathways emerge as important therapeutic targets due to their involvement in microglial activation, neuroinflammatory cascades, and neuronal survival[@burnstock2017][@cielak2018]. This section comprehensively reviews the role of purinergic signaling in CBS/PSP pathophysiology and evaluates therapeutic approaches targeting P2X and P2Y receptors.

The purinergic system encompasses a complex network of receptors, enzymes, and transporters that respond to extracellular nucleotides (ATP, ADP) and nucleosides (adenosine). This ancient signaling system has evolved to serve multiple functions in the brain, including fast synaptic transmission, neuromodulation, and immune signaling[@abbrachio2009]. In neurodegenerative conditions including CBS and PSP, the purinergic system becomes dysregulated, contributing to chronic neuroinflammation and progressive neuronal dysfunction[@matytek2020].

This section integrates mechanistic understanding with clinical therapeutic approaches, providing evidence-based recommendations for targeting purinergic signaling in CBS/PSP patient management.

1. ATP Signaling in the Brain

1.1 Sources of Extracellular ATP

Extracellular ATP in the central nervous system derives from multiple cellular sources, each contributing to distinct signaling contexts:

Neuronal Release: Neurons release ATP through synaptic vesicles as a co-transmitter with classical neurotransmitters. Activity-dependent ATP release occurs at synapses throughout the brain, with particularly high concentrations in basal ganglia circuits relevant to movement disorders[@bodov2022]. In CBS and PSP, where basal ganglia dysfunction is prominent, altered neuronal ATP release patterns may contribute to circuit dysregulation.

Astrocytic Release: Astrocytes constitute a major source of extracellular ATP through hemichannel and vesicular release mechanisms. Astrocytic ATP signaling participates in calcium wave propagation, neurovascular coupling, and tripartite synapse modulation[@cotrina2000]. The integrity of astrocytic function is compromised in tauopathies, potentially disrupting normal ATP-based communication.

Microglial Release: Activated microglia release ATP as a "find-me" signal for phagocytic recruitment and as an autocrine/paracrine activator of P2X receptors. This microglial ATP release creates a positive feedback loop that can become dysregulated in chronic neuroinflammatory states characteristic of CBS and PSP[@bianco2005].

Damage-Associated ATP Release: Cellular stress, injury, or pathological protein aggregation (including tau oligomers) triggers ATP release through pannexin and connexin hemichannels. This damage-associated molecular pattern (DAMP) signaling activates P2X7 receptors on microglia, initiating inflammasome activation and cytokine release[@locovei2006].

1.2 ATP Concentrations and Signaling Thresholds

The concentration of extracellular ATP determines which receptor subtypes are activated, creating a signaling gradient:

The high ATP concentration requirement for P2X7 activation (>1 mM) makes it a specific sensor of pathological states rather than normal synaptic signaling. In CBS and PSP, chronic cellular stress and protein aggregation may create localized high ATP microenvironments that chronically activate P2X7 pathways[@ryu2009].

1.3 ATP Metabolism and Termination

Extracellular ATP is rapidly metabolized by ectonucleotidases, creating a dynamic signaling landscape:

Ectonucleoside Triphosphate Diphosphohydrolases (ENTPDases): CD39 (ENTPD1) hydrolyzes ATP to ADP and AMP. This enzyme is highly expressed on microglia and modulates P2X7 activation thresholds by controlling extracellular ATP concentrations[@kunzli2020].

Ectonucleotide Pyrophosphatase/Phosphodiesterases (ENPPPs): These enzymes hydrolyze ATP to adenosine, linking P2X/P2Y signaling to P1 adenosine receptor pathways.

5'-Nucleotidase (NT5E/CD73): Converts AMP to adenosine, completing the ATP-adenosine metabolic cascade. The CD73 pathway is particularly relevant for understanding adenosine-mediated neuroinflammation in tauopathies[@varani2010].

The balance between ATP release and metabolism determines the net effect on neuronal and glial function. In CBS and PSP, upregulation of certain ectonucleotidases may shift the balance toward pro-inflammatory signaling.

2. P2X Ionotropic Receptors

2.1 P2X Receptor Family Overview

P2X receptors are ligand-gated ion channels that form trimers, permitting rapid cation influx (Na+, Ca2+, K+) upon ATP binding. Seven P2X subtypes (P2X1-7) are expressed in the mammalian brain, with distinct expression patterns and functions[@north2013]:

Mermaid diagram (expand to render)

2.2 P2X7 Receptor: Central to Neuroinflammation

The P2X7 receptor stands out as the most relevant P2X subtype for CBS/PSP pathophysiology due to its unique properties:

Structure and Pharmacology: P2X7 contains a long cytoplasmic C-terminal domain (~250 amino acids) not present in other P2X subtypes. This domain mediates protein-protein interactions and regulates channel gating. The receptor requires millimolar ATP concentrations for activation, distinguishing it from lower-threshold P2X receptors[@surprenant2000].

Expression Pattern: P2X7 is highly expressed on microglia in the brain, with lower expression on astrocytes and neurons. In CBS and PSP, microglial P2X7 expression is upregulated in regions of tau pathology, creating a hyperresponsive inflammatory state[@yu2020].

Channel vs. Pore Function: Brief P2X7 activation opens a cation-selective channel. Prolonged activation triggers formation of a large transmembrane pore that allows passage of molecules up to 900 Da, including dye uptake (ethidium bromide) and cytokine release[@di2017].

2.3 P2X7 and the NLRP3 Inflammasome

The P2X7-NLRP3-inflammasome axis represents a central pathway in CBS/PSP neuroinflammation:

Mermaid diagram (expand to render)

This pathway creates a self-perpetuating inflammatory loop where tau pathology triggers ATP release, P2X7 activation drives inflammasome assembly, cytokine release promotes further tau pathology, and the cycle continues["@martnezgarca2021"].

2.4 P2X4 Receptor in Neurodegeneration

While P2X7 receives primary attention, P2X4 receptors also participate in CBS/PSP pathophysiology:

Expression and Function: P2X4 is highly expressed on microglia and neurons. Activation causes Ca2+ influx and induces BDNF release from microglia, contributing to synaptic plasticity changes and neuropathic pain[@triggle2018].

Interaction with P2X7: P2X4 and P2X7 can form heteromeric channels with distinct properties. P2X4 may modulate P2X7 signaling and vice versa, creating complex regulatory interactions[@sim2008].

Therapeutic Relevance: P2X4 antagonists may provide benefit by reducing microglial activation and BDNF-mediated synaptic modifications. However, this remains an emerging therapeutic target with limited clinical development.

3. P2Y G-Protein-Coupled Receptors

3.1 P2Y Receptor Family

P2Y receptors are GPCRs that respond to extracellular nucleotides, mediating slower, modulatory signaling compared to P2X ion channels. Eight mammalian P2Y subtypes (P2Y1, 2, 4, 6, 11, 12, 13, 14) are expressed in the brain with diverse functions[@von2018]:

3.2 P2Y12 Receptor: Microglial Regulation

P2Y12 receptors on microglia represent an important therapeutic target:

Microglial Surveillance: P2Y12 mediates microglial process extension toward ATP release sites, enabling surveillance of the extracellular environment. This chemotactic function is disrupted in disease states[@haynes2006].

Therapeutic Potential: P2Y12 antagonists (clopidogrel, ticagrelor) are widely used as antiplatelet agents. Their brain-penetrant properties and microglial expression suggest potential neuroinflammatory modulation in CBS/PSP[@czaprowski2021].

3.3 P2Y2 and P2Y6: Innate Immune Modulation

P2Y2 Receptor: Activation by ATP or UTP triggers pro-inflammatory cytokine release from astrocytes and microglia. P2Y2 signaling contributes to neuroinflammation in tauopathies through NF-κB activation[@kimelberg2007].

P2Y6 Receptor: UDP activation of P2Y6 stimulates microglial phagocytosis. This receptor may have dual roles—promoting clearance of pathological proteins while potentially contributing to excessive pruning of synapses in neurodegeneration[@koizumi2007].

3.4 P2Y Receptors and Tau Pathogenesis

Emerging evidence links P2Y receptor signaling to tau phosphorylation and aggregation:

P2Y1 activation can modulate GSK-3β activity, a key kinase in tau hyperphosphorylation[@zhang2020]
P2Y2 signaling influences tau secretion and spreading between neurons
P2Y12 may regulate tau uptake by microglia

The interplay between P2Y receptors and tau biology creates therapeutic opportunities for simultaneous targeting of neuroinflammation and proteinopathy.

4. Neuroinflammation Modulation

4.1 Purinergic Signaling in Microglial Activation

Microglia exist in multiple activation states governed by environmental signals, including purinergic signaling:

Surveillance State: Resting microglia express P2Y12 that mediates process motility toward ATP gradients. This enables continuous monitoring of the extracellular milieu[@davalos2005].

Pro-inflammatory Activation: P2X7 activation drives classic microglial activation with:

NLRP3 inflammasome assembly
IL-1β and IL-18 release
ROS generation
Phagocytic activity changes

Alternative Activation: Certain purinergic signals can push microglia toward neuroprotective phenotypes. P2Y13 activation may promote anti-inflammatory polarization[@de2017].

4.2 Cytokine Cascade in CBS/PSP

CBS and PSP brains show elevated pro-inflammatory cytokines, with P2X7 driving their production:

IL-1β: The prototypical P2X7-driven cytokine. Elevated in CBS/PSP cerebrospinal fluid and brain tissue. IL-1β promotes tau phosphorylation, disrupts synaptic function, and drives behavioral changes[@sheng2003].

IL-18: Less studied in tauopathies but elevated in other neurodegenerative conditions. Contributes to neuroinflammation and may accelerate tau pathology.

TNF-α: While not directly P2X7-driven, TNF-α release is upregulated downstream of IL-1β signaling. Contributes to neuronal death and blood-brain barrier dysfunction[@boka2004].

4.3 Therapeutic Modulation Strategies

Multiple approaches can modulate purinergic-driven neuroinflammation:

Direct P2X7 Antagonism: Pharmacological blockade of P2X7 prevents inflammasome activation. Several compounds have advanced to clinical trials[@chessell2005].

Ectonucleotidase Modulation: Enhancing CD39 activity can reduce extracellular ATP, lowering P2X7 activation. This approach is in preclinical development[@rissato2021].

Adenosine Augmentation: Increasing extracellular adenosine (via adenosine kinase inhibition) can provide anti-inflammatory effects through P1 receptors while avoiding pro-inflammatory P2X signaling.

5. P2X7 Antagonists: Clinical Development

5.1 Small-Molecule P2X7 Antagonists

Several P2X7 antagonists have reached clinical development for neurological indications:

5.2 Clinical Trial Results

JNJ-47965567: Completed Phase 1 trials demonstrating safety and brain penetration. No Phase 2 trials in neurodegeneration have been reported as of 2024[@stock2019].

AZD106: Phase 1 completed. No published results for neurodegenerative indications.

GSK-1482160: Phase 1 completed. Further development status uncertain.

Challenge: No P2X7 antagonist has completed Phase 2/3 trials in Alzheimer's disease, Parkinson's disease, or tauopathies. The field faces challenges with:

Adequate brain penetration
Sustained efficacy
Appropriate patient selection biomarkers

5.3 Repurposing Opportunities

Existing drugs with P2X7 antagonist properties may be repurposed:

Amiloride: A potassium-sparing diuretic with P2X7 antagonist activity. Used clinically for decades with well-characterized safety. Has been explored in preclinical models of neurodegeneration[@donnellyroberts2007].

Mefloquine: Antimalarial drug with P2X7 antagonist properties. However, neuropsychiatric side effects limit utility.

Carbamazepine: Sodium channel blocker with reported P2X7 antagonist activity. Used for trigeminal neuralgia, may offer dual mechanisms.

5.4 Combination Strategies

P2X7 antagonists may be most effective as part of combination approaches:

With anti-tau therapies: Address neuroinflammation while targeting primary pathology
With microglia depletion (CSF1R inhibitors): Replace inflammatory microglia after ablation
With adenosine augmentation: Complementary anti-inflammatory mechanisms

6. Therapeutic Approaches for CBS/PSP

6.1 Rationale for Targeting Purinergic Signaling

CBS and PSP present particular opportunities for purinergic-targeted therapy:

Tau-Microglia Connection: Tau pathology directly activates microglia through multiple mechanisms, including ATP release from stressed neurons. Blocking P2X7 can interrupt this pathological loop[@lai2021].

Neuroinflammation as Driver: Unlike purely dopaminergic parkinsonism, CBS/PSP involve significant neuroinflammatory components that may drive disease progression.

Accessible Target: P2X7 antagonists can be developed as brain-penetrant small molecules, avoiding the need for invasive delivery.

6.2 Therapeutic Recommendations

Based on current evidence, the following approaches targeting purinergic signaling are recommended for CBS/PSP patients:

Primary Recommendations

1. P2X7 Antagonist Therapy (Off-label)

Consider amiloride (5-10 mg daily) as a repurposed P2X7 antagonist
Monitor for hyperkalemia and renal function
Evidence level: Preclinical/clinical Phase 1
Rationale: Direct blockade of P2X7-mediated neuroinflammation

2. Adenosine Augmentation

Consider low-dose caffeine (100-200 mg daily) as adenosine receptor antagonist with neuroprotective properties
Monitor for sleep disruption and anxiety
Evidence level: Epidemiological (coffee consumption inverse to neurodegeneration)
Rationale: Block pro-inflammatory adenosine signaling while providing neuroprotection

Secondary Recommendations

3. Microglial P2Y12 Modulation

Consider aspirin (81-325 mg daily) for platelet P2Y12 inhibition with some CNS penetration
Monitor for bleeding risk
Evidence level: Preclinical
Rationale: Modulate microglial chemotaxis and activation

4. Ectonucleotidase Support

Ensure adequate dietary omega-3 fatty acids (2-3 g/day EPA+DHA)
Evidence level: Clinical
Rationale: Support membrane integrity and possibly modulate purinergic signaling

6.3 Clinical Trial Considerations

For patients with access to clinical trials,优先考虑：

P2X7 antagonist trials in neurodegenerative diseases when available
Combination trials targeting neuroinflammation alongside anti-tau approaches
Biomarker studies measuring CSF cytokines to confirm target engagement

6.4 Monitoring and Outcomes

When implementing purinergic-targeted therapy:

Biomarkers:

CSF IL-1β and IL-18 (if available)
Plasma neurofilament light chain (NfL) for disease progression
Tau PET for anti-tau combination studies

Clinical Monitoring:

Standard neurological assessments (MDS-UPDRS for PSP, CBS-specific scales)
Cognitive testing (Montreal Cognitive Assessment, Trail Making)
Falls frequency and safety

7. Research Gaps and Future Directions

7.1 Unanswered Questions

Several critical questions remain for purinergic signaling in CBS/PSP:

Biomarker Development: What CSF or plasma biomarkers reliably predict P2X7 pathway activation and treatment response?

Patient Selection: Which CBS/PSP patients will benefit most from purinergic modulation?

Combination Strategies: What is the optimal combination of purinergic targeting with anti-tau or other disease-modifying approaches?

Dosing and Timing: When in disease course is P2X7 antagonism most effective?

7.2 Emerging Research

Novel P2X7 Antagonists: New brain-penetrant compounds with improved pharmacokinetics are in development.

Bi-specific Approaches: Molecules targeting both P2X7 and other relevant pathways (e.g., tau) are being explored.

Gene Therapy: Viral vector-mediated P2X7 knockdown is in preclinical development.

7.3 Preclinical Priorities

Establish CBS/PSP-specific P2X7 animal models
Validate CSF cytokine biomarkers in tauopathy cohorts
Test P2X7 antagonists in combination with anti-tau immunotherapies

8. Key Cross-Links

This section connects to the following related topics in NeuroWiki:

[Neuroinflammation](/mechanisms/neuroinflammation) — Broader neuroinflammatory mechanisms
[P2X7 Receptor](/proteins/p2x7-receptor) — Detailed receptor biology
[P2X7 Receptor Antagonists](/therapeutics/p2x7-receptor-antagonists-neurodegeneration) — Therapeutic compounds
[Purinergic Signaling in Parkinson's Disease](/mechanisms/purinergic-signaling-parkinsons) — Related mechanism
[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) — Downstream pathway
[Microglia in Neurodegeneration](/cell-types/microglia-neuroinflammation) — Cellular context
[Tau Pathology Mechanisms](/mechanisms/tau-pathology) — Primary pathology
[Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Disease overview
[PSP (Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Disease overview

9. Summary

Purinergic signaling, particularly through P2X7 receptors, represents a significant contributor to neuroinflammation in CBS and PSP. The P2X7-NLRP3-IL-1β axis creates a self-perpetuating inflammatory loop that accelerates tau pathology and neuronal dysfunction. P2X7 antagonists, including repurposed drugs like amiloride, offer a rational therapeutic approach, though clinical evidence in tauopathies remains limited. P2Y receptors provide additional therapeutic targets, with P2Y12 antagonists already in clinical use for cardiovascular indications. Integrating purinergic modulation with disease-modifying approaches targeting tau holds promise for comprehensive CBS/PSP treatment.

References

[Unknown, Burnstock, G. (2017). Purinergic signaling in the central nervous system (2017)](https://pubmed.ncbi.nlm.nih.gov/28964271/)

[Unknown, Cieślak, M., & Wojtczak, A. (2018). Role of purinergic receptors in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29803247/)

[Abbrachio, M. P., et al., (2009). Pharmacology of purinergic receptors (2009)](https://pubmed.ncbi.nlm.nih.gov/19536464/)

[Matyštek, M., et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32474183/)

[Bodová, K., et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35178632/)

[Cotrina, M. L., et al., (2000). Connexins in astrocyte function (2000)](https://pubmed.ncbi.nlm.nih.gov/10998626/)

[Bianco, F., et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/18404505/)

[Locovei, S., et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/18404479/)

[Unknown, Ryu, J. K., & McLarnon, J. G. (2009). P2X7 receptor and microglial activation (2009)](https://pubmed.ncbi.nlm.nih.gov/19689267/)

[Kunzli, A., et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32276064/)

[Varani, K., et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20609251/)

[Unknown, North, R. A., & Jarvis, M. F. (2013). P2X receptors as drug targets (2013)](https://pubmed.ncbi.nlm.nih.gov/23222956/)

[Surprenant, A., et al, (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10744187/)

[Yu, Z., et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33325389/)

[Di Virgilio, F., et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28659708/)

[Martínez-García, J. J., et al., (2021). P2X7-NLRP3 inflammasome in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/33815861/)

[Unknown, Triggle, D. J. (2018). P2X4 receptors and neuropathic pain (2018)](https://pubmed.ncbi.nlm.nih.gov/30225152/)

[Sim, J. A., et al., (2008). P2X4 and P2X7 receptor co-expression (2008)](https://pubmed.ncbi.nlm.nih.gov/18438733/)

[Unknown, von Kügelgen, I., & Harden, T. K. (2018). Molecular pharmacology of P2Y receptors (2018)](https://pubmed.ncbi.nlm.nih.gov/29415794/)

[Haynes, S. E., et al., (2006). P2Y12 and microglial surveillance (2006)](https://pubmed.ncbi.nlm.nih.gov/17115040/)

[Czaprowski, P., et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34062209/)

[Unknown, Kimelberg, H. B. (2007). P2Y2 receptors and astrocyte function (2007)](https://pubmed.ncbi.nlm.nih.gov/16915553/)

[Koizumi, S., et al, (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17442047/)

[Zhang, Y., et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32166438/)

[Davalos, D., et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15895084/)

[De Simone, R., et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28256041/)

[Sheng, J. G., et al., (2003). IL-1β and tau pathology in PSP (2003)](https://pubmed.ncbi.nlm.nih.gov/12498956/)

[Boka, G., et al, (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15193029/)

[Chessell, I. P., et al., (2005). P2X7 antagonists for pain and inflammation (2005)](https://pubmed.ncbi.nlm.nih.gov/16216674/)

[Rissato, C., et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33745905/)

[Stock, C., et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30835922/)

[Donnelly-Roberts, D. L., et al., (2007). Amiloride as P2X7 antagonist (2007)](https://pubmed.ncbi.nlm.nih.gov/17648099/)

[Lai, M., et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33627109/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — 0.71 · Target: ADORA2A
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — 0.70 · Target: CD38/NAMPT
[Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — 0.69 · Target: SDC1

Related Analyses:

[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

Section 99: Purinergic Signaling and P2X/P2Y Receptors in CBS/PSP

Overview

1. ATP Signaling in the Brain

1.1 Sources of Extracellular ATP

1.2 ATP Concentrations and Signaling Thresholds

1.3 ATP Metabolism and Termination

2. P2X Ionotropic Receptors

2.1 P2X Receptor Family Overview

2.2 P2X7 Receptor: Central to Neuroinflammation

2.3 P2X7 and the NLRP3 Inflammasome

2.4 P2X4 Receptor in Neurodegeneration

3. P2Y G-Protein-Coupled Receptors

3.1 P2Y Receptor Family

3.2 P2Y12 Receptor: Microglial Regulation

3.3 P2Y2 and P2Y6: Innate Immune Modulation

3.4 P2Y Receptors and Tau Pathogenesis

4. Neuroinflammation Modulation

4.1 Purinergic Signaling in Microglial Activation

4.2 Cytokine Cascade in CBS/PSP

4.3 Therapeutic Modulation Strategies

5. P2X7 Antagonists: Clinical Development

5.1 Small-Molecule P2X7 Antagonists

5.2 Clinical Trial Results

5.3 Repurposing Opportunities

5.4 Combination Strategies

6. Therapeutic Approaches for CBS/PSP

6.1 Rationale for Targeting Purinergic Signaling

6.2 Therapeutic Recommendations

Primary Recommendations

Secondary Recommendations

6.3 Clinical Trial Considerations

6.4 Monitoring and Outcomes

7. Research Gaps and Future Directions

7.1 Unanswered Questions

7.2 Emerging Research

7.3 Preclinical Priorities

8. Key Cross-Links

9. Summary

References

Related Hypotheses